🇺🇸 FDA
Patent

US 9326950

Self-assembling nanoparticles composed of transmembrane peptides and their application for specific intra-tumor delivery of anti-cancer drugs

granted A61KA61K9/5169A61P

Quick answer

US patent 9326950 (Self-assembling nanoparticles composed of transmembrane peptides and their application for specific intra-tumor delivery of anti-cancer drugs) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Apr 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue May 03 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K9/5169, A61P, A61P35/00, A61P35/04